Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics’ VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

First-in-Class TEAD Autopalmitoylation Inhibitor is Well Tolerated and Demonstrates Antitumor Activity in Advanced Mesothelioma and NF2-Mutant Cancers VT3989 is the First Therapeutic Targeting the Hippo Pathway to Demonstrate Clinical Activity in Patients with Cancer SAN MATEO, Calif.,…